Beijing-based Healthstar Medical Development Co., Ltd (SHA: 603590) has announced that the National Medical Products Administration (NMPA) has accepted a clinical trial filing for its Category 1 chemical drug, KC1036, for a pediatric indication. This development signifies a significant step forward in the exploration of new treatment options for pediatric cancer patients in China.
KC1036: A Multi-Targeted Small-Molecule Cancer Therapy
KC1036 is a small-molecule cancer therapy that targets AXL, VEGFR2, and FLT3, key proteins involved in cancer growth and progression. The drug is currently the subject of multiple clinical studies, reflecting its potential in addressing various types of cancer. These include a Phase Ib/II study in advanced recurrent or metastatic digestive system tumors, a Phase II study in advanced thymic tumors, and another Phase II study in previously treated advanced non-driving-gene lung adenocarcinoma in combination with docetaxel.
Clinical Studies and Patient Enrollment
Over 100 patients with different advanced solid tumors have been enrolled across these multiple studies, providing a broad evaluation of KC1036’s safety and efficacy. The drug has demonstrated good clinical safety and efficacy in these trials, which is crucial for its potential approval and use in pediatric cancer treatment.-Fineline Info & Tech
